• 5657威尼斯(中国)

      Global
      关于5657威尼斯(中国)

      致力于纳米抗体创新药物研发

      关于5657威尼斯(中国)
      科研论文
      截止现在，5657威尼斯(中国)生物研发团队在具有重要影响力的期刊上发表研究论文多篇。
      2023-11-06
      TROP2-directed nanobody-drug conjugate elicited potent antitumor effect in pancreatic cancer
      发表于:J Nanobiotechnology. 2023 Nov 6;21(1):410
      查看更多内容
      2023-09-21
      Identification and Characterization of a Novel Nanobody Against Human CTGF to Reveal Its Antifibrotic Effect in an in vitro Model of Liver Fibrosis
      发表于:Int J Nanomedicine. 2023 Sep 21;18:5407-5422
      查看更多内容
      2022-11-19
      Preclinical development of a long-acting trivalent bispecific nanobody targeting IL-5 for the treatment of eosinophilic asthma
      发表于:Respiratory Research. 2022 Nov 19;23(1):316
      查看更多内容
      2022-10-24
      Screening, Expression, and Identification of Nanobody against SARS-CoV-2 Spike Protein
      发表于:Cells. 2022 Oct 24;11(21):3355
      查看更多内容
      2022-10-03
      Atomically dispersed Mn boosting photoelectrochemical SARS-CoV-2 spike protein immunosensing on carbon nitride
      发表于:Journal of Environmental Chemical Engineering. 2022 Dec;10(6):108697
      查看更多内容
      2022-07-22
      Evaluation of SARS-CoV-2-neutralizing Nanobody Using Virus Receptor Binding Domain Administered Model Mice-Research-2022
      发表于:Research (Wash D C). 2022 Jul 22;2022:9864089
      查看更多内容
      总计 24 1234